In the current study, we investigated a novel vascular catheter (the CS2) that incorporated a silver sulfadiazine (S) and chlorhexidine (C) and released antimicrobials from the surface for longer periods of time in vitro and in vivo. CS1 was compared to CS2 catheters (the CS1 catheter), which are available commercially. As indicated by different methods, A 48- hour study of Staphylococcus aureus and five other bacteria found that the CS2 catheter produced a slightly smaller inhibition zone (mean difference, 0.9 mm, P 0.001) than the CS1 catheter antibiotic-resistant bacteria. At the time of catheter placement, rabbits were also administered 104 to 107 CFU of Staphylococcus aureus, There were no complications with either CS catheter equally effective in preventing catheter infection. The catheter is more likely to prevent infection when its exterior surface is sustained anti-infective